The findings were consistent in patients switched to Angiox monotherapy from unfractionated heparin or Sanofi-Aventis's Lovenox (enoxaparin). The Medicines Company recently re-acquired rights for Angiox in Europe and currently markets the product as Angiomax in the US.
Lead author of the study, Harvey White, director of Coronary Care and Cardiovascular Research at Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand, said: “The reduction in early bleeding achieved with Angiox monotherapy is particularly important, as bleeding events are commonly linked to late mortality in these patients.”